TARGET AUDIENCE: Medical, surgical and radiation oncologists and other healthcare professionals involved in the management of breast cancer.

GLOBAL LEARNING OBJECTIVES:
Upon completion of this activity, participants should be able to:

• Develop an evidence-based treatment algorithm for the initial and extended adjuvant management of ER-positive early breast cancer, integrating knowledge gleaned from recent clinical advances and ongoing trials with aromatase inhibitors and tamoxifen.
• Review the current clinical approach and ancillary laboratory testing to support selection of endocrine therapy for the patient with chemotherapy-induced amenorrhea or a perimenopausal presentation.
• Utilize standard clinical factors and novel tissue biomarkers to individualize cytotoxic, endocrine and/or biologic therapy in the early and advanced breast cancer treatment settings.
• Describe the unique risks and benefits of acceptable single-agent and combination chemotherapy and endocrine regimens, and use this information to tailor treatment decisions for patients with metastatic disease.
• Explore the emerging role of growth factor inhibition and anti-angiogenesis in the management of breast cancer, and explain the investigational rationale and safety implications for combining these agents with standard therapeutic interventions.
• Counsel appropriately selected patients about the availability and relevance of ongoing breast cancer clinical trials.

CME EVALUATION: An evaluation form will be given to each participant at the conclusion of this educational activity.

ACCREDITATION STATEMENT: Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT: Research To Practice designates this educational activity for a maximum of 2.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

DISCLOSURE POLICY: As a provider accredited by the Accreditation Council for Continuing Medical Education, it is the policy of Research To Practice to require the disclosure of any significant financial interest or any other relationship the sponsor or faculty members have with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. Financial disclosures and disclosures of discussions of unlabeled/unapproved uses of drugs or devices will be provided in meeting course materials.

EDUCATIONAL SUPPORT: This event is supported by education grants from Abraxis BioScience and AstraZeneca Pharmaceuticals LP.